Amylyx reports $22.2M full-year product revenue; net loss $198.4M

Amylyx Pharmaceuticals, Inc.

Q4 net product revenue $21.9M; full-year 2022 net product revenue $22.2M from RELYVRIO/ALBRIOZA sales.
Net loss for 2022 was $198.4M ($3.39 per share) vs. $87.9M in 2021; cash & short-term investments $346.9M.
Phase 3 PHOENIX trial fully enrolled (664 participants); topline data expected mid-2024.
EU MAA regulatory review ongoing; company now expects CHMP opinion mid-2023 and decision Q3 2023 at earliest.
Karen Firestone appointed to Board of Directors effective March 16; raised $230.6M net in October 2022 public offering.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.97

Amylyx Pharmaceuticals, Inc. reported the fourth quarter and full year ended December 31, 2022 results: revenue $21.9 million, net income $42.7 million, or $0.65 per share.

Period: the fourth quarter and full year ended December 31, 2022
Revenue: $21.9 million
Net income: $42.7 million, or $0.65 per share
Result: reported results

Exact text from the filing

For the three months ended December 31, 2022, net product revenue was $21.9 million

View on SEC.gov

Browse all earnings releases →

Amylyx Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-007580

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.